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Abstract
Osteopontin (Opn) is a cytokine involved in both physiological and pathological processes, and is 
elevated in many autoimmune diseases. Sjögren’s syndrome (SS) is an autoimmune disease with a 
strong female predilection characterized by lymphocytic infiltration of exocrine glands. We 
hypothesized Opn contributes to SS pathogenesis. We examined an established SS model, and 
found increased Opn locally and systemically. Next, we examined Opn transgenic (Opn Tg) mice 
for evidence of SS. Opn Tg animals exhibited lymphocytic infiltration of salivary and lacrimal 
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glands, and Opn co-localized with the infiltrates. Moreover, saliva production was reduced, and 
SS autoantibodies were observed in the serum of these mice. Finally, female Opn Tg mice showed 
more severe disease compared to males. Taken together, these data support a role for Opn in SS 
pathogenesis. We identify a new model of spontaneous SS that recapitulates the human disease in 
terms of sex predilection, histopathology, salivary deficits, and autoantibodies.
1. Introduction
Osteopontin (Opn) is a multifunctional protein with diverse physiological functions. Opn 
was originally isolated, cloned, and sequenced from the rat osteosarcoma cell-line ROS 
17/2.8. The name “osteopontin” was thought to reflect its potential to form a bridge between 
osteoid cells and matrix [1]. Opn is now known to have a wide tissue distribution and is 
expressed by many immune cells including macrophages, dendritic cells, and lymphocytes 
[2–6]
Although Opn has important functions in many tissues, it is also implicated in several 
disease processes. Interestingly, Opn is associated with numerous autoimmune diseases in 
both humans as well as animal models, including systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA), multiple sclerosis (MS), and type I diabetes [7–13]. 
Polymorphisms in OPN are also implicated in organ specific autoimmune diseases. For 
example, polymorphisms in the OPN alleles are observed in young type I diabetic patients 
[13] Moreover, OPN is identified as a new RA susceptibility gene [14]. Importantly, there 
are two recent studies that show increased Opn in serum and salivary tissue of patients with 
Sjögren’s syndrome (SS) [15, 16], although the role of Opn in SS remains poorly 
understood. Thus, many autoimmune conditions exhibit elevated Opn, and this is strongly 
correlated with disease development in both humans and in animal models.
Like most autoimmune diseases, SS displays a strong female predilection. The diagnosis of 
SS is complicated, and currently includes a compilation of both subjective and objective 
symptoms and signs [17], although recent work has resulted in a new preliminary diagnostic 
profile for SS that proposes removal of the subjective criteria from the current diagnostic 
algorithm [18]. Patients with SS typically display xerostomia and xerophthalmia, and also 
have lymphocytic infiltrates in salivary and lacrimal tissue. In addition, serological 
expression of anti-SSA (Ro) and/or anti-SSB (La) autoantibodies are included as part of the 
diagnostic criteria. An ideal SS mouse model should display characteristics similar to those 
seen in human SS including the aforementioned clinical, histological, and serological 
features [19].
Given the relationship between Opn and other autoimmune conditions, we hypothesized that 
Opn is important in the etiology and pathogenesis of SS. To determine whether Opn may be 
linked pathogenically to SS disease, we first examined Opn levels in the well-established 
NOD/ShiLtJ (NOD) SS model [20]. Opn expression was elevated in salivary gland tissue 
from these mice as compared to controls. We then sought to determine whether over-
expression of Opn plays a role in SS pathogenesis. To this end, we used a murine model in 
which transgenic Opn expression is driven by an immunoglobulin enhancer/promoter [21]. 
Our results show that this model displays many features of human SS, and thus represents an 
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excellent model to study this disease. The Opn transgenic (Opn Tg) model will prove a 
valuable tool in the study of this debilitating condition and further support the study of Opn 
as a previously unappreciated mediator in SS pathogenesis.
2. Materials and Methods
2.1. Mice
BALB/c, NOD/ShiLtJ (NOD) and C57BL/6 mice were obtained from the Jackson 
Laboratory. Opn Tg mice in which Opn expression is driven by the immunoglobulin 
enhancer/SV40 promoter were kindly provided by Dr. Uede from Hokkaido University, 
Japan [21]. These mice were backcrossed with C57BL/6 mice for a total of 13 generations. 
Mice were cared for and handled in accordance with Institutional Animal Care and Use 
Committee and National Institutes of Health guidelines.
2.2. Sera collection
Sera from Opn Tg mice were harvested at 18–31 weeks of age and from NOD mice at 16 
weeks of age. Healthy age and gender matched C57BL/6 and BALB/c mice were used as 
controls. Mice were bled by cardiac puncture following euthanasia. Samples were placed at 
room temperature for two hours, and centrifuged at 3,000 rpm for 20 minutes. Samples were 
collected and stored at −20°C prior to use.
2.3. Isolation of exocrine tissue
Submandibular salivary gland (SMG) and lacrimal gland tissue were removed following 
euthanasia. Tissue was fixed in 10% buffered formalin or frozen for mRNA analysis.
2.4. mRNA isolation and quantitative PCR (qPCR)
mRNA was isolated from B and T cells and whole SMG tissue using a RNeasy kit (Qiagen). 
Reverse transcription was performed using an iScript kit (BioRad). qPCR was performed 
using SYBR green (BioRad), as previously described [17, 22]. Primers were as follows: 
Actin: Forward 5′ GCTACAGCTTCACCACCACA 3′, Reverse: 5′ 
TCTCCAGGGAGGAAGAGGAT 3′, Gapdh: Forward 5′ 
GCAGTGGCAAAGTGGAGATT 3′, Reverse: 5′ GAATTTGCCGTGAGTGGAGT 3′, and 
Opn: Forward: 5′ GACAACAACGGAAAGGGCAG 3′, Reverse: 5′ 
GATCGGCACTCTCCTGGCT 3′. All samples were analyzed in duplicate and Opn 
expression normalized to Actin or Gapdh. PCR settings were as follows: 50 °C for 2 min, 95 
°C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. PCR data were 
analyzed by ΔCT.
2.5. Immunobloting analysis
Proteins were extracted from B and T cell pellets with radio-immunoprecipitation assay lysis 
buffer. In each experiment, equal amounts of protein for each condition were subjected to 
SDS-PAGE followed by immunoblotting as previously described [23]. Immunoreactive 
proteins were detected by ECL (Amersham Biosciences). Immunoblots were stripped and 
reprobed with control antibody to verify equal amounts of protein were loaded in each lane.
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2.6. ELISA
Sera were harvested as described above. Serum anti-Ro autoantibody titers (Alpha 
Diagnostics), total IgM, IgA, IgG (Bethyl Laboratories), and Opn levels (R&D Systems) 
were assessed by ELISA according to the manufacturer’s instructions.
2.7. HEp-2 Staining
HEp-2 slides (MBL Bion) were incubated with diluted mouse sera (1:100) from female Opn 
Tg (n=4, 16 wks) and female C57BL/6 mice (n=4, 16 wks). Slides were stained with a 
polyvalent anti-immunoglobulin-FITC antibody (Sigma). Images were acquired using a 
fluorescence microscope (Zeiss Axiovert 200M) with a FITC filter.
2.8. Assessment of disease development
Hematoxylin and eosin (H&E) stained salivary and lacrimal gland tissues were examined for 
lymphocytic infiltrates. Lymphocytic foci consisting of at least 50 cells per high power field 
were considered indicative of SS disease, as previously described (16).
2.9. Saliva collection and quantification
Pilocarpine HCl (0.3 mg/100 μL) was injected intraperitoneally (Sigma-Aldrich), and saliva 
was collected for 10 minutes. Saliva was immediately placed on ice, centrifuged briefly, and 
quantified using a pipette. All samples were stored at −20° C prior to study.
2.10. B cell isolation and activation
B cells were isolated from spleens of C57BL/6 and Opn Tg mice by negative selection using 
magnetic beads (Miltenyi Biotech) and resuspended in culture medium consisting of RPMI 
1640 medium supplemented with L-glutamine (2 mM), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (20 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2-
mercaptoethanol (50 mM) and 10% FCS. The isolated B cells were treated with F(ab′)2 
fragments of goat ant-mouse IgM at 15 μg/ml (anti-Ig) (Jackson ImmunoResearch) and 
cultured for 4 days.
2.11. In vitro [3H] thymidine assay
B cells were isolated from spleens of C57BL/6 and Opn Tg mice by negative selection, and 
cultured as described above. B cells were seeded at a density of 1 x 105 cells/ 0.1 ml 
medium in a 96-well culture plate. On day 4 of culture, cells were pulsed with 0.5 
microcurie/well of [3H] thymidine for 6 hours. Cells were then harvested, and incorporation 
of [3H] thymidine was quantified using a scintillation counter (Beckman Coulter).
2.12. Assessment of cell viability by flow cytometry
Splenic B cells isolated from C57BL/6 and Opn Tg mice were cultured for 1, 2, 3 and 5 
days, as described above. At the end of each incubation period, cell viability was assessed 
using propidium iodide (1 mg/ml) by flow cytometry. Data was acquired using a LSRII flow 
cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star).
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2.13. Cytokine Quantification
Sera were harvested as described above and Interleukin-4 (IL-4), IL-6, IL-2 and TNF-α 
were quantified by multiplex ELISA cytokine array using Q-Plex™ technology (Quansys 
Biosciences). Q-Plex™ technology involves the micro-spotting of individual groups of 
capture antibody in either a cartesian or polar coordinate system on the bottom of a 96 well 
plate, each spot being its own micro ELISA. Each well is identically spotted. Standard 
ELISA incubation steps apply such as initial sample incubation, washing, secondary 
antibody incubation, washing, incubation with the chemiluminescent label and 
measurement.
2.14. Immunohistochemistry and histopathology
Formalin fixed, paraffin embedded tissue was stained with H&E using the Symphony 
automated platform (Ventana). Immunohistochemistry (IHC) was performed on salivary 
tissue with an IntelliPATH autostainer (BioCare Medical) using an Opn antibody (0.07 
μg/mL) (LifeSpan Biosciences). An isotype control (Abcam) was used at the same 
concentration.
3. Results
3.1. Opn is increased in salivary tissue and serum of NOD animals
To determine whether Opn is pathogenically linked to SS disease, we assessed Opn 
expression in serum and SMG tissue using the well-characterized NOD SS model. NOD 
animals develop spontaneous SS disease in a highly predictable time frame [20]. To 
determine whether salivary Opn is elevated in SS, we isolated SMG tissue from NOD 
females with clinical disease and age and gender matched BALB/c controls. We found that 
NOD animals have higher expression of Opn compared to healthy controls (Figure 1A). 
Then, we assessed Opn in sera to determine whether it is elevated systemically. Opn is 
significantly increased in the NOD animals (n=5) compared to controls (n=5) (Figure 1B). 
To assess Opn expression in the context of disease development, we examined SMG tissue 
from female NOD mice at the pre-disease (4 weeks of age, n=5), pre-clinical disease (12 
weeks of age, n=5) and clinical disease stages (16 weeks of age, n=5). Age and gender 
matched BALB/c mice were used as controls. We found that Opn is increased in the SMG of 
NOD mice with clinical disease, whereas there was no difference in Opn expression at the 
pre-disease or pre-clinical disease time points (Figure 1C). This indicates that Opn 
expression in the SMG of NOD mice correlates with the development of SS-like features in 
these animals.
We then examined the SMG tissue of clinical disease stage NOD (n=3) and control BALB/c 
females (n=3) for Opn expression by IHC. We observed Opn expression by salivary gland 
ducts in both NOD and control BALB/c mice as previously reported [24, 25]. Of note, Opn 
expression was also seen in the lymphocytes infiltrating the SMG tissue of NOD animals 
(Figure 1D). This infiltration is termed focal lymphocytic sialadenitis (FLS), and is a 
hallmark of SS in both murine models and SS patients [17]. Thus, this finding suggests that 
the increased Opn observed at the clinical disease stage in the SMG gland of NOD mice is 
most likely due to expression by the infiltrating lymphocytes. Thus Opn is elevated in 
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salivary tissue and systemically in SS-afflicted NOD mice, suggesting a role for Opn in SS 
pathogenesis.
3.2. B cells have increased Opn compared to T cells in Opn Tg mice
Next, we sought to confirm that Opn is elevated in B cells derived from Opn Tg animals. 
We evaluated Opn Tg mice in which Opn expression is driven by the immunoglobulin 
heavy chain promoter, and thus is thought to be primarily B cell derived [21]. Accordingly, 
previous studies demonstrate B220+ cells from Opn Tg mice express significantly higher 
amounts of Opn compared to B220− cells [21]. To confirm these data, we purified splenic B 
and T cells from Opn Tg animals and C57BL/6 controls using magnetic beads and measured 
Opn expression by qPCR. In agreement with prior studies, we found Opn transcripts are 
markedly elevated in splenic B cells from the Opn Tg mice compared to T cells from the 
same animals (Figure 2A). We also evaluated Opn protein levels in Opn Tg animals. 
Similarly, we observed increased Opn levels in splenic B cells as compared to T cells 
(Figure 2B and C). Of note, unstimulated B and T cells from wild type mice do not express 
Opn mRNA or protein as previously shown [6]. Although these experiments were conducted 
in male mice, females had similar Opn levels (data not shown). Thus, B cells from Opn Tg 
animals produce significantly more Opn than T cells.
3.3. B cells from Opn Tg animals show enhanced survival and mitogenesis
Since Opn Tg animals express B cell derived Opn [21], we examined B cells from these 
animals to determine if they demonstrated enhanced survival and mitogenic activity 
compared to controls. To assess survival, we measured cell viability using propidium iodide. 
Flow cytometric analysis revealed increased numbers of viable B cells derived from Opn Tg 
mice (Figure 3A). In addition, Opn Tg B cells showed increased mitogenic activity in 
response to B cell receptor engagement by anti-IgM F(ab′)2 fragments as compared to 
C57BL/6 controls (Figure 3B). Thus, B cells derived from Opn Tg animals have enhanced 
survival and proliferative capacity.
3.4. Female Opn Tg mice express serum autoantibodies characteristic of SS
Since Opn is increased in NOD SS mice as well as Opn Tg animals, we sought to determine 
whether elevated Opn contributes to SS pathogenesis. To this end, we examined both IgG 
and IgM from Opn Tg animals and C57BL/6 controls. We assayed for autoantibodies using 
an autoantigen array as an initial screening tool. Results from this array indicated a 
substantial increase in antibodies directed against SSA (Ro60 and Ro52) in female Opn Tg 
serum as compared to serum from male Opn Tg animals, and male and female C57BL/6 
controls (data not shown). To confirm this, we examined sera from Opn Tg females (n=14, 
15–19 weeks) and age and sex matched C57BL/6 controls (n=9) by ELISA. In accordance 
with the autoantigen array data, we found that female Opn Tg mice have higher titers of 
anti-SSA autoantibodies (Figure 4A). Finally, we used Hep-2 substrate slides to detect anti-
nuclear autoantibodies in serum by indirect immunofluorescence. Strikingly, sera from 
female Opn Tg mice (n=4, 16–18 weeks) showed significantly more autoreactivity than 
C57BL/6 control sera (n=4, 16–18 weeks) or sera from male Opn Tg mice (n=4, 16–18 
weeks) (Figure 4B).
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Since Opn Tg animals express elevated levels of autoantibodies, we sought to confirm that 
the increase in autoantibodies was not due to heightened antibody production. To this end, 
we performed ELISAs to quantify serum IgM, IgA and IgG levels in Opn Tg females and 
age and gender matched C57BL/6 controls. As expected we observed an increase in serum 
IgM levels in the Opn Tg animals, although total IgA and IgG were comparable in both 
groups (Supplementary Figure 1). Notably, the anti-SSA levels (all isotypes) in Opn Tg 
mice were increased 1.83 fold, while the IgM titers were increased 1.56 fold and the IgG and 
IgA titers were not increased at all. These data indicate that the increase autoantibodies 
observed in Opn Tg females is not solely due to higher antibody titers seen in these animals. 
Thus, these results suggest Opn Tg mice recapitulate the female disease predominance 
observed in human SS as evidenced by enhanced autoantibody production.
3.5. Histopathological findings consistent with SS are evident in salivary and lacrimal 
gland tissue from female Opn Tg mice
Next, we examined salivary and lacrimal tissue from female Opn Tg mice for FLS. Mice 
and humans have 3 major salivary glands: parotid, sublingual and submandibular. We 
focused our analyses on the SMG, since this is the largest salivary gland in mice, and this 
gland shows evidence of FLS that is similar to the human disease and also present in other 
SS models [26, 27]. Initially, animals were assayed between the ages of 5 and 14 weeks, and 
lymphocytes were not observed in SMG tissue at this early time point (n=10) (data not 
shown). Importantly, we found FLS within the salivary tissue in 10 out of 16 female Opn Tg 
mice beginning at 16 weeks of age. Lymphocytes were absent in SMG tissue from age and 
sex matched controls (n=8) (Figure 5A and B). In addition, we examined lacrimal tissue 
from 8 of the 16 animals for histologic changes consistent with SS. Significantly, 4 of 8 Opn 
Tg animals demonstrated lymphocytic infiltration of this tissue that was absent in controls. 
Of note, only 2 of 16 animals showed both salivary as well as lacrimal infiltrates (Figure 5C, 
D, E and F). Taken together, 12 of 16 (75%) of Opn Tg animals exhibited lymphocytic 
infiltration of salivary and/or lacrimal gland tissue, suggesting this model demonstrates 
histopathologic features consistent with human SS. These results are summarized in table 1.
3.6. Opn is expressed by ductal epithelium and co-localizes with the lymphocytic infiltrates 
in SMG tissue from female Opn Tg mice
In mice, Opn is normally expressed by submandibular seromucous acini and ductal 
epithelium [24, 25]. We performed IHC to determine which cells within the salivary tissue 
express Opn in diseased Opn Tg animals. We demonstrate that Opn co-localizes with 
lymphocytic infiltrates within SMG tissue. In addition, Opn is expressed by ductal 
epithelium in SMG tissue, and these findings were seen in both Opn Tg and control animals 
as expected (Figure 6A, B and C). In addition, we used immunoblotting to confirm these 
results as shown in figure 6D and E. We observed increased Opn levels in SMG tissue of 
Opn Tg animals as compared to controls. These findings demonstrate that female Opn Tg 
mice show histologic features of SS, and lymphocytic infiltrates within the SMG express 
Opn.
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3.7. Opn transgenic animals exhibit decreased saliva production
Loss of salivary flow is a hallmark of SS disease and is included as part of the diagnostic 
criteria [17]. Although the cause of xerostomia in SS is not completely understood, 
autoantibodies, apoptosis of glandular tissue, polymorphisms in inflammatory genes, and 
lymphocytic infiltration of salivary tissue may all contribute to loss of saliva [27–30]. To 
determine whether Opn Tg animals exhibit decreased salivary flow, we assayed production 
of stimulated saliva following intraperitoneal injection with the parasympathetic agonist, 
pilocarpine. Notably, we found female Opn Tg mice (16–20 weeks old) produced 
significantly less saliva than age and sex matched control animals (Figure 7). These results 
demonstrate functional deficits in saliva production in these mice that mimic findings seen 
in human subjects with SS.
3.8. Inflammatory cytokines are elevated in the serum of female Opn Tg mice
To determine whether cytokines that are elevated in human SS are also increased in Opn Tg 
mice, we performed a multiplex ELISA assay. Sera were isolated from female Opn Tg (n=6, 
16–18 weeks old) and C57BL/6 mice (n=5, 16–18 weeks old). We observed a significant 
increase in IL-4, IL-6, IL-2 and TNF-α levels in the sera from Opn Tg mice as compared to 
healthy controls (Figure 8). These findings are consistent with those seen in human pSS 
patients [31–33]. Therefore, the serum cytokine profile of female Opn Tg mice resembles 
that of human pSS patients.
4. Discussion
We show, for the first time, a disease phenotype in Opn Tg animals, suggesting a role for B 
cell derived Opn in SS development. It is well established that Opn plays a role in the 
pathogenesis of autoimmune diseases such as SLE, MS, Type I diabetes, and RA, although 
the role of Opn in SS has not been clarified [13, 15, 16]. Results from our study show NOD 
mice with clinical disease express increased Opn in both salivary tissue and serum. Further, 
Opn Tg animals display histologic evidence of SS disease in both salivary and lacrimal 
gland tissue, and show diminished saliva production. Opn Tg females express elevated anti-
SSA autoantibodies. Thus, the Opn Tg mouse represents a new model of pSS that closely 
mimics the human disease.
The Opn Tg model is particularly valuable because it will allow for examination of Opn in 
the context of SS pathogenesis. Importantly, these mice develop spontaneous pSS in a 
relatively short time frame not always seen in other pSS models [34]. We found that 75% of 
all female animals examined at 18–24 weeks of age showed lymphocytic infiltration of 
glandular tissue and most animals had significantly decreased saliva production. These 
animals breed well, and we have not observed development of extraneous malignancies 
reported in other pSS models [35]. Thus Opn Tg animals represent an excellent model in 
which to study SS, as the disease develops spontaneously and is more severe in females.
Good murine models are needed to facilitate the study of SS because the etiology of the 
disease is unknown, and factors responsible for its progression are poorly understood. The 
role of the microbiome is an emerging area in autoimmune research, and studies implicate 
the host microbiota in type I diabetes, and RA [36–38]. A recent report showed that 
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bacterially-derived peptides mimic the amino acid sequence and structure of an SS 
autoantigen (Ro60), and some of these peptides activate Ro60 specific T cells [39]. While 
the significance of commensal or pathogenic bacteria in SS remains unclear, this is an 
important area of SS research that needs further exploration.
Regardless of the cause of SS, elevated inflammatory cytokines are characteristic of this 
disease. We performed multiplex ELISA to determine whether cytokines that are elevated in 
human SS are also increased in female Opn Tg mice [31–33, 40–42]. We found elevated 
levels of IL-4, IL-6, IL-2 and TNF-α in the sera of these animals, although the cellular 
source of these cytokines in our model is unclear. Opn can act on numerous cell types, and 
data suggest Opn may skew T helper subsets towards Th1, Th17 or Th2 depending on the 
inflammatory stimulus [43–45]. Alterations in normal CD4+ T helper (Th) subset ratios are 
observed in SS [46]. The Th17 subset is also activated pathogenically, and the T regulatory 
subset is also dysregulated [32, 47]. While T cells were classically considered to be the 
primary source of cytokines in SS, there is significant evidence showing B cells are also 
integral to disease [48, 49]. Opn is a known polyclonal B cell activator [50], and increased 
Opn expression may result in secretion of B cell derived pro-inflammatory cytokines [51, 
52].
For example, fibroblast-like synoviocytes from RA patients produce Opn, and in co-culture 
experiments with B cells, B cell derived IL-6 production was enhanced [53]. A study of 
patients with Crohn’s disease examined the relationship between Opn and TNF-α using in 
vivo activated T cells from these individuals. Interestingly, Opn enhanced T cell derived 
TNF-α secretion in a dose dependent manner [54]. Moreover, there is a positive correlation 
between Opn and IL-2 levels in diseased lung tissue in a pulmonary fibrosis model, and 
incubation with IL-2 results in increased expression of Opn by human bile duct epithelial 
cells [55, 56]. Thus, it is possible that Opn and IL-2 have a positive feedback loop and work 
together to influence biological functions [57].
Similar to IL-2, IL-4 and Opn were both elevated in liver tissue in a steatohepatitis model 
[58, 59]. While it is known that stimulation of B cells with IL-4 along with B-cell receptor 
engagement results in Opn production [6], the effect of Opn on IL-4 production is less clear. 
Studies using Opn deficient animals demonstrate decreased IL-4 production in the invariant 
natural killer T cell population [60], and asbestos treated Opn−/− animals have reduced IL-4 
expression in bronchoalveolar lavage samples [61]. Thus, these studies suggest that a 
relationship exists between OPN and IL-4 induction, but whether this extends to B cells 
specifically remains to be determined.
Aside from its effects on inflammatory cytokine production, Opn is a powerful 
chemoattractant for macrophages and NK cells, and these cells could be an important source 
of inflammatory cytokines locally within the salivary tissue in SS [62, 63]. The effect of 
Opn on NK cells is particularly intriguing, especially given the emerging role of NK cells in 
SS disease. A recent study shows that a polymorphism in the NK cell soluble activating 
receptor (NCR3/NKp30) promoter conferred protection against pSS. Moreover, systemic 
levels of NCR3/NKp30 are increased in pSS patients, and the ligand for this receptor is 
expressed by salivary epithelial cells [64]. Significantly, Opn may be a positive regulator of 
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NK cell development, as Opn deficient mice show impaired development of NK cells in the 
bone marrow and spleen. Moreover, paracrine Opn signaling is crucial for NK-lineage 
commitment [65]. A separate study examined Opn in the context of Influenza A virus 
infection and found an increased number of NK cells induced by Opn [66]. Thus, it is 
possible that Opn expression influences NK cell activity and number, and this may 
contribute to SS progression.
Importantly, Opn exerts anti-apoptotic effects on T cells, and dendritic cells, as well as 
monocytes and macrophages [67–70]. We observed Opn affects B cells in the same way, as 
cultured Opn Tg B cells show increased survival and mitogenesis. Significantly, similar 
findings were seen in wild type B cells stimulated with recombinant Opn. The means by 
which Opn leads to increased survival of B cells is unclear. Studies in MS models and 
human patients suggest B cell activating factor (BAFF) induces B cell derived Opn that 
maintains T cell survival through upregulation of the anti-apoptotic protein Bcl-2 [71]. 
Importantly, high levels of BAFF are documented in SS mouse models and pSS patients 
[72–74]. Thus, Opn and BAFF may work in concert to enhance survival and expansion of 
self-reactive B cells in SS. This could represent an important mechanism leading to loss of B 
cell tolerance in SS.
B cell abnormalities are well documented in SS, and therapies that deplete B cells, such as 
the anti-CD20 antibody rituximab, have shown modest success in treating the disease [75–
77]. However, in rare cases this therapy results in life threatening infection, and so other 
more targeted therapies would be of significant clinical value [78]. A study using a collagen 
induced arthritis model demonstrated anti-Opn antibody therapy resulted in apoptosis of 
activated T cells and reduced levels of inflammatory cytokines in sera [79]. More recently, 
the safety and efficacy of this approach was demonstrated in human RA patients [80]. Thus, 
this strategy may be effective in SS patients, as Opn blockade will likely have fewer side 
effects than the B cell depletion therapies currently in use to treat autoimmunity.
Together the results herein provide evidence that B cell derived Opn plays a role in SS 
development. While further studies are needed to determine whether this effect is B cell 
intrinsic in human disease, it is clear that Opn has potent effects on many cells types and is 
crucial to development of autoimmunity in several models. Opn has not been carefully 
studied in the context of SS, and the Opn Tg model will serve as a valuable resource to 
examine the significance of Opn in SS disease. Moreover, further studies are warranted in 
humans to determine whether Opn is a potential therapeutic target in SS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Osteopontin (Opn) is elevated in several autoimmune diseases.
• Opn transgenic (Opn Tg) mice are a new model for Sjögren’s syndrome (SS).
• Female Opn Tg mice show more severe disease compared to males.
• Opn Tg animals exhibit lymphocytic infiltration of salivary and lacrimal glands.
• Opn Tg mice have reduced saliva and increased SS autoantibodies.
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Figure 1. Opn is increased in SMG tissue and serum of NOD mice
(A) NOD females (n=5, 16 weeks old) with late stage disease were euthanized and salivary 
glands harvested. SMG from age and gender matched BALB/c mice were used as controls 
(n=5). Tissue was homogenized, and relative Opn transcript levels were quantified by qPCR. 
Each sample was analyzed in duplicate and normalized expression relative to Actin is 
shown. (B) Serum Opn levels were assessed by ELISA. Each sample was analyzed in 
duplicate. Significance was determined using the Mann-Whitney test (**p<0.01) and 
(*p<0.05), and mean and SEM are shown. (C) SMG tissue was harvested from NOD 
females with pre-disease (n=5, 4 weeks old), pre-clinical (n=5, 12 weeks old), and clinical 
disease (n=5, 16 weeks old). Relative Opn expression was quantified by qPCR as described 
in (A). (D) Immunohistochemical staining was performed on SMG tissue from Opn Tg 
female animals and BALB/c controls (16 weeks old). Opn is identified by brown staining. 
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Samples were counterstained with hematoxylin, which appears blue. Representative staining 
from 3 animals is shown. Scale bars are shown in the lower right of each photomicrograph 
(original magnification 400X).
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Figure 2. B cells have increased Opn compared to T cells in the Opn Tg mice
Spleens were obtained from Opn Tg mice and B cells were isolated using magnetic beads. 
(A) mRNA was isolated and reverse transcribed. Relative Opn transcript levels were 
quantified by qPCR. Each individual sample was analyzed in triplicate and normalized 
expression relative to Actin from three independent experiments is shown. Error bars 
represent SEM. Significance was determined using the Mann-Whitney test (**p<0.01). (B) 
Cell lysates from B and T cells from Opn transgenic mice were subjected to immunoblotting 
using antibody directed against Opn. Membranes were stripped and re-probed with Gapdh 
specific antibody as a loading control. (C) Immunoblot analysis data represented as fold 
change. Significance was determined using the Mann-Whitney test (**p<0.01). (B) 
Represents one of three independent experiments and (C) represents mean fold change of all 
three experiments. (A to C) All mice were male and 14–16 weeks of age.
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Figure 3. B cells from Opn Tg mice demonstrate enhanced survival and mitogenesis
(A) Viability of B cells from Opn Tg (16 weeks old, n=3) and control C57BL/6 mice (16 
weeks old, n=3) was evaluated using propidium iodide following culture for 1, 2, 3, and 5 
days. (B) Tritiated thymidine incorporation assays were done using Opn Tg (16 weeks old, 
n=3) and C57BL/6 control B cells (16 weeks old, n=3). Isolated B cells were treated with 
F(ab′)2 fragments of goat ant-mouse IgM at 15 μg/ml (anti-Ig) (Jackson ImmunoResearch) 
and cultured for 4 days. Each assay was repeated three times, and representative experiments 
are shown. Significance was determined using the Mann-Whitney test (*p<0.05), and 
(****p<0.0001), and SEM is shown.
Husain-Krautter et al. Page 20
Clin Immunol. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. SS Autoantibodies are increased in female Opn Tg mice
(A) An anti-Ro ELISA was conducted using sera from Opn Tg (n=14, 15–19 weeks) and 
control C57BL/6 mice (n=9, 15–19 weeks old). Samples were analyzed in duplicate. 
Significance was determined using the Mann-Whitney test (**p<0.01), and mean and SEM 
are shown. (B) HEp-2 staining was performed using sera from female Opn Tg (n=4, 16 wks 
old), male Opn Tg (n=4, 16 wks old) and control female C57BL/6 mice (n=4, 16 wks old) 
and a representative example from each group is shown.
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Figure 5. Opn Tg mice have exocrine histopathology consistent with human SS
Lymphocytic infiltration was assessed in salivary gland (A) and lacrimal gland tissue (B) of 
female control C57BL/6 mice and salivary (C and E) and lacrimal gland tissue (D and F) 
from age and sex matched Opn Tg mice (C, D, E and F). All animals were 18–24 weeks of 
age. Representative staining from at least 8 animals is shown. Black arrows represent 
lymphocytic infiltration, and white arrows indicate ducts. Scale bars are shown in lower 
right of each photomicrograph (original magnification 400X).
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Figure 6. Opn is expressed by SMG ductal epithelium of female Opn Tg mice
Immunohistochemical staining was performed on SMG tissue from Opn Tg female animals 
and C57BL/6 control female animals (n=4, 20 weeks old). Staining for Opn (A and C) and 
isotype control (IC) (B and D) is shown. Brown staining represents expression of the 
indicated protein. All samples were counterstained with hematoxylin, which appears blue. 
Representative staining from 3 animals is shown. Scale bars are shown in the lower right of 
each photomicrograph (original magnification 100X). (E) Cell lysates from SMG of Opn Tg 
and C57BL/6 mice were subjected to immunoblotting using antibody directed against Opn. 
Membranes were stripped and re-probed with Gapdh specific antibody as a loading control. 
(F) Immunoblot analysis data represented as fold change. Significance was determined using 
Mann-Whitney test (**p<0.01). (E) Represents one of three independent experiments and 
(F) represents mean fold change of all three experiments. (E and F) All mice were female 
and 18–20 weeks of age.
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Figure 7. Female Opn Tg animals exhibit decreased saliva production
Whole stimulated saliva was collected from Opn Tg (n=14) and control animals (n=14). All 
animals were 16–20 weeks of age. Significance was determined using the Mann-Whitney 
test (***p<0.001), and mean and SEM are shown.
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Figure 8. Inflammatory cytokines are elevated in the serum of Opn Tg mice
Sera from female Opn Tg (n=5, 16–18 weeks old) and control female C57BL/6 mice (n=5, 
16–18 weeks old,) were assayed by multiplex ELISA. Significance was determined using 
the Mann-Whitney test (**p<0.01) and (*p<0.05). Each sample was analyzed in triplicate, 
and mean and SEM are shown
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Table 1
Animal # of infiltrates (SMG) # of infiltrates (lacrimal)
1 2 0
2 0 1
3 1 1
4 0 0
5 3 0
6 0 0
7 1 1
8 0 1
9 1 N.D.
10 0 N.D
11 1 N.D
12 0 N.D
13 1 N.D
14 4 N.D
15 2 N.D
16 1 N.D
N.D. = Not determined
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